<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214122</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00013</org_study_id>
    <secondary_id>2010-022360-12</secondary_id>
    <nct_id>NCT01214122</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin</brief_title>
  <official_title>A Phase I, Open Label, Fixed Sequence, Single Centre Study in Healthy Volunteers to Investigate the Effects of Repeated Oral Doses AZD9668 on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether the treatment with AZD9668 will
      affect the metabolism and effect of Warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics measured by maximum international normalised ratio ( INRmax)</measure>
    <time_frame>International normalised ratio (INR) sampling will be performed day 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for AZD9668 measured by Css,max</measure>
    <time_frame>Range from day 9 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for AZD9668 measured by tss,max</measure>
    <time_frame>Range from day 9 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for AZD9668 measured by Css,min</measure>
    <time_frame>Range from day 9 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for AZD9668 measured by CLss/F</measure>
    <time_frame>Range from day 9 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Adverse events will be collected pre-dose, during treatment and at follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Adverse events will be collected pre-dose, during treatment and at follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin measured tmax.</measure>
    <time_frame>Range from day 1 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin measured t½.</measure>
    <time_frame>Range from day 1 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin measured CL/F.</measure>
    <time_frame>Range from day 1 to 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)- Warfarin measured Vz/F.</measure>
    <time_frame>Range from day 1 to 23</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9668 - 2 x30mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin - 10 x2.5 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>60 mg orally twice daily for 11 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>10 x 2.5 (25) mg orally once daily on day 1 and on day 14</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed informed consent (including genotyping screening sample for CYP2C9
             and VKORC1) prior to any study specific procedures

          -  Subjects must be willing to use a barrier method of contraception, unless their
             partners are post-menopausal or surgically sterile, or if a female partner is of
             childbearing potential the subject must use a barrier method of contraception (condom)
             and the partner must use accepted contraceptive methods (oral contraceptive, implant,
             long term injectable contraceptive or intrauterine device), from first dose of IP
             (warfarin and AZD9668) until 3 months after last dose of IP (warfarin and AZD9668)

          -  Have a body mass index between 19 and 30 kg/m2 (inclusive) and a weight between 50 and
             100 kg (inclusive)

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to Visit 1.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Subject predicted to have high sensitivity to warfarin based on CYP2C9 and VKORC1
             genotypes

          -  Any clinically relevant abnormal findings in physical examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D O'Brien, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar Bylesjö, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berzelius Clinical Reseach Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kühn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Phase 1 Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>warfarin</keyword>
  <keyword>AZD9668</keyword>
  <keyword>resulting from AZD9668 and Warfarin interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

